Logo
    Search

    omicron variant

    Explore "omicron variant" with insightful episodes like "Encore: 5 Tips to Prepare for a Flight Cancelation", "#192 - COVID Part 2: Masks, long COVID, boosters, mandates, treatments, and more", "Omicron Mitigation, Djokovic, Dumb COVID Tweets", "A Covid Testing Crisis, Again" and "Safety Precautions For The Holiday Season" from podcasts like ""Money Rehab with Nicole Lapin", "The Peter Attia Drive", "The VPZD Show", "The Daily" and "Short Wave"" and more!

    Episodes (8)

    #192 - COVID Part 2: Masks, long COVID, boosters, mandates, treatments, and more

    #192 - COVID Part 2: Masks, long COVID, boosters, mandates, treatments, and more

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Episode Description:

    This episode is a follow-up to our recent COVID-19 podcast with Drs. Marty Makary and Zubin Damania (aka ZDoggMD). Here, we address many of the listener questions we received about our original discussion. In addition to Marty and ZDoggMD, we are also joined by Dr. Monica Gandhi, an infectious disease specialist and Professor of Medicine at the University of California, San Francisco. In this episode, we talk about new data on Omicron, long COVID, masks, kids and schools, vaccine mandates, policy questions, and treatments. We also discuss some of the most prevalent misinformation and spend time talking about claims made by Robert Malone. We end with a conversation about our exit strategy. 

    Please note: we recorded this episode on January 17, 2022, and in an effort to get it out as soon as possible, this won’t have full show notes or a video. Additionally, Monica was only able to join us for the first section of the podcast, so you’ll hear her drop off partway through.

    We discuss:

    • Severity of infection from Omicron—reviewing the data [5:15];
    • Factors contributing to the relative mildness of Omicron infections [8:30];
    • Is SARS-CoV-2 evolving to cause less severe disease? [13:00];
    • Potential of Covaxin—an inactivated virus-based COVID-19 vaccine [17:45];
    • How B cells and T cells work together to defend against viruses [22:00];
    • Comparing COVID-19 vaccines, and the rationale for the time between doses [25:30];
    • Reviewing the purpose and effectiveness of boosters for reducing severity and transmission [32:30];
    • Debating vaccine mandates, and putting COVID’s mortality risk in perspective [41:00];
    • Why the topic of COVID has become so polarized [1:03:15]  
    • Reviewing the data on masks for protecting oneself and protecting others [1:06:30];
    • The inconsistent logic used for mask mandates [1:16:00]; 
    • Long COVID and the potential for vaccines to reduce risk [1:21:45];
    • Risks for children and policies for schools [1:27:30];
    • Reviewing the outcomes from Sweden, where the government didn't impose lockdowns [1:31:00];
    • Draconian measures implemented in Canada [1:38:15]; 
    • Antiviral treatments for COVID and a common-sense approach [1:42:15];
    • Importance of ending tribalism and having rational discussions with humility [1:47:30];
    • Treating infection with monoclonal antibodies and convalescent sera [2:01:45];
    • Reviewing claims made by the controversial Dr. Robert Malone [2:11:15];
    • A potential exit strategy from the current situation [2:30:30];
    • Changes needed at the NIH [2:40:00];
    • More.

    Sign Up to Receive Peter’s Weekly Newsletter

    Connect With Peter on TwitterInstagramFacebook and YouTube

    Omicron Mitigation, Djokovic, Dumb COVID Tweets

    Omicron Mitigation, Djokovic, Dumb COVID Tweets
    In this Omi-sode: 1) Can omicron be mitigated AT ALL? The Bay Area experience currently. 2) Novak Djokovic and the COVID vaccine 3) Covidiots vs. Covidians, where is the Alt-Middle? Rogan's role. 4) The dumbest tweets of 2021 5) Who was most right about COVID policy? Subscribe to "The VPZD Show" on your favorite podcast app. Check out our new Substack collaboration, "Sensible Medicine" here. Dr. Prasad's "Plenary Session" podcast. Dr. Damania's "ZDoggMD Show" podcast. More on Vinay. More on Zubin. Learn more about your ad choices. Visit megaphone.fm/adchoices

    A Covid Testing Crisis, Again

    A Covid Testing Crisis, Again

    By the end of last year, if you needed a coronavirus test, you could get one. But when vaccines arrived, focus shifted.

    Many of the vaccinated felt like they didn’t need tests and demand took a nosedive. Testing sites were closed or converted into vaccination sites. And Abbott Laboratories, a major test manufacturer, wound up destroying millions.

    However, with the surge of the new Omicron variant, which is less susceptible to vaccines, demand for testing is back — and it is outstripping supply.

    Guest: Sheryl Gay Stolberg, a Washington correspondent, covering health policy for The New York Times.

    Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. 

    Safety Precautions For The Holiday Season

    Safety Precautions For The Holiday Season
    The Omicron variant is spreading across the U.S. as the holidays are upon us. Science Desk reporter Maria Godoy has the latest on the variant and tips for reducing your risk of contracting the virus this holiday season. Short Wave brings you a special episode courtesy of our colleagues at Life Kit.

    Learn more about sponsor message choices: podcastchoices.com/adchoices

    NPR Privacy Policy

    RANT: Omicron Variant Hitting Travel & Leisure Hard [Business, mindset, entrepreneur, disruptors]

    RANT: Omicron Variant Hitting Travel & Leisure Hard [Business, mindset, entrepreneur, disruptors]

    We must stand together and support businesses and the economy. In this episode, Rob talks about the impact the new restrictions and changes are having, especially for smaller businesses and wants to know what can be done to help.

    KEY TAKEAWAYS 

    • Travel giants like TUI and Best Western are struggling, so how do we think smaller businesses are coping?
    • Rob supported the furlough scheme and other smaller schemes in previous restrictions. But what are the government doing now to help? Are there things we can do as individuals to help?
    • If something happens in the world that is unforeseen and businesses can’t operate, the government needs to step in and help. It's our job as individuals to push for this and help provide ideas and solutions.
    • Too many people don’t see the true benefits of the economy: it matters. Small businesses make up for a very large proportion of the economy, as much as 90% in some cases.

    BEST MOMENTS 

     “Business drives the economy, anything that you need to survive a business, an entrepreneur has created”

    “It stops when we stand up”

    “What are we going to do to support small businesses?”

    [Business, mindset, entrepreneur, disruptors]

    VALUABLE RESOURCES

    https://robmoore.com/

    bit.ly/Robsupporter  

    https://robmoore.com/podbooks

     rob.team

    ABOUT THE HOST

    Rob Moore is an author of 9 business books, 5 UK bestsellers, holds 3 world records for public speaking, entrepreneur, property investor, and property educator. Author of the global bestseller “Life Leverage” Host of UK’s No.1 business podcast “Disruptors”

    “If you don't risk anything, you risk everything”

    CONTACT METHOD

    Rob’s official website: https://robmoore.com/

    Facebook: https://www.facebook.com/robmooreprogressive/?ref=br_rs

    LinkedIn: https://uk.linkedin.com/in/robmoore1979

    disruptive, disruptors, entreprenuer, business, social media, marketing, money, growth, scale, scale up, risk, property: http://www.robmoore.com

    What A New Antiviral Drug Could Mean For The Future Of COVID

    What A New Antiviral Drug Could Mean For The Future Of COVID
    An advisory panel to the U.S. Food and Drug Administration advisory panel has voted to recommend that the FDA approve a new antiviral drug to treat COVID-19. The FDA decision is expected soon. Host Emily Kwong chats with health reporter Pien Huang on the state of treatments and how this drug and other treatment options may change the pandemic.

    For more of Pien's reporting, check out "New antiviral drugs are coming for COVID. Here's what you need to know." <>

    You can follow Emily on Twitter @EmilyKwong1234 and Pien @Pien_Huang. Email Short Wave at ShortWave@NPR.org.

    Learn more about sponsor message choices: podcastchoices.com/adchoices

    NPR Privacy Policy

    Omicron: Do You Need to Freak Out?

    Omicron: Do You Need to Freak Out?
    Welp, the pandemic has served up yet another poop sandwich, and it’s called omicron. This variant is popping up in dozens of countries across the world, and scientists are racing to get a handle on it. So how bad could this be? And could it sneak past our vaccines? To find out, we talk to virologist and immunologist Professor Ann Sheehy, Prof. Art Wallace, epidemiologist Dr. Barbara Cohn, immunologist Dr. Ali Ellebedy and virologist Dr. John Tembo. UPDATE 12/6/21: A previous version of this episode incorrectly said that genes tell our bodies how to make amino acids -- it’s been corrected to say that genes tell our bodies how to string together amino acids. Find our transcript here: https://bit.ly/31rpKit This episode was produced by Wendy Zukerman, Rose Rimler, Meryl Horn, Michelle Dang, and Ekedi Fausther-Keeys. We’re edited by Blythe Terrell. Fact checking by Nick DelRose. Mix and sound design by Bumi Hidaka. Music written by Bumi Hidaka, Peter Leonard, Emma Munger and Bobby Lord. Thanks to the researchers we got in touch with for this episode, including Prof. Paul Bieniasz, Katarina Grande, and Prof. David O'Connor. Special thanks to Mia Malan, Musa Malaza, Hunter, Jack Weinstein, the Zukerman family Rachel Ward and Joseph Lavelle Wilson. Learn more about your ad choices. Visit podcastchoices.com/adchoices